Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Immutep TACTI-004 NSCLC Trial At 50% Enrolment, Paving Way for Futility Analysis
Immutep (ASX: IMM) has achieved a significant milestone, announcing 50% patient enrolment in its global Phase III TACTI-004 trial for first-line non-small ce
Latest Stories
Island Pharmaceuticals Raises $9m to Fund Clinical Development as FDA Approves Galidesivir Pathway
Island Pharmaceuticals (ASX: ILA) secures FDA Animal Rule path for galidesivir and $9m funding to fast-track two-stage trials and US govt procurement potential.
Rhythm Biosciences Secures Key Manufacturing Deal for ColoSTAT
Rhythm Biosciences (ASX:RHY) has secured a multi-year manufacturing agreement with Quansys Biosciences for its ColoSTAT reagent kits, ensuring scalab
Neurotech International Secures HREC Approval for Pivotal Phase 3 ASD Study of NTI164
Neurotech International (ASX: NTI) has secured Human Research Ethics Committee (HREC) approval to commence its pivotal Phase 3 clinical study for **NTI16
Algorae Pharmaceuticals Advances Commercial Pathway as AI Platform Validation and Distribution Agreements Gather Pace
Algorae Pharmaceuticals (ASX: 1AI) advances AlgoraeOS validation and signs Dr Reddy's distribution, signals near-term oncology revenue and stronger balance sheet.
Osteopore Expands Orthopaedic Business into Hong Kong with MontsMed Distribution Agreement
Osteopore (ASX: OSX) is set to expand its orthopaedic business into Hong Kong after signing a new distribution agreement with local company MontsMed, marking the next step in the company’s planned commercial expansion across the Asia Pacific region.
Zelira Therapeutics Receives US$33m in Funding to Advance HOPE 1 Autism Program
Zelira Therapeutics (ASX: ZLD) has secured US$32.98 million in new funding after its HOPE 1 special purpose vehicle signed definitive agreements with US-based life sciences investor ThirdGate Capital's TGC Biotechnology Fund.
Proteomics International Obtains Canadian Patent for PromarkerEso Blood Test
Proteomics International Laboratories (ASX: PIQ) has secured new intellectual property protection in Canada, after the country’s Patent Office granted a patent for its PromarkerEso blood test for esophageal adenocarcinoma.
NeuroScientific Biopharmaceuticals Reports Strong Results from Stem Cell Study on Fistulising Crohn's Disease
NeuroScientific Biopharmaceuticals (ASX: NSB) has confirmed that 75% of patients in the first cohort of a study into its StemSmart therapy to treat fistulising Crohn’s disease have demonstrated a positive clinical response following treatment.
Biome Australia Surges with 41% YoY Revenue Growth in Q2 FY26
Biome Australia (ASX: BIO) has reported a robust Q2 FY26, with revenue surging 40.9% year-on-year to $6.48 million, significantly exceeding expectations and reinforcing its trajectory towards its 'Vis
AdAlta inks major CAR-T deal for global development outside China
AdAlta (ASX:1AD) has secured exclusive rights to co-develop Shanghai Cell Therapy Group's BZDS1901 CAR-T therapy outside Greater China, a significant move validating its 'East-to-West' strategy and po
Memphasys Secures CE Mark for Felix System, Unlocking European Market
Memphasys (ASX: MEM) has secured CE Mark approval for its Felix System, unlocking immediate commercial opportunities in Europe and activating binding multi-year contracts in Europe and MENA.